Dermatomyositis Pipeline Review: H1 2018 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

June 11, 2018

DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Dermatomyositis - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev’s Disease) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 9, 6, 5, 13, 8 and 2 respectively.

Companies Mentioned

AbbVie Inc Adello Biologics LLC Alteogen Inc Amgen Inc Biocad Biocon Ltd Bionovis SA Celgene Corp Coherus BioSciences Inc Eli Lilly and Co Fresenius SE & Co KGaA Galapagos NV Genor BioPharma Co Ltd Immunwork Inc Innovent Biologics Inc Izana Bioscience Ltd Mycenax Biotech Inc Nichi-Iko Pharmaceutical Co Ltd Novartis AG Nuevolution AB Oncobiologics Inc Pfizer Inc Protalix BioTherapeutics Inc Reliance Life Sciences Pvt Ltd Sandoz International GmbH Shanghai Pharmaceutical Co Ltd Sun Pharma Advanced Research Company Ltd UCB SA Xbrane Biopharma AB

Key Topics Covered

Introduction Ankylosing Spondylitis (Bekhterev’s Disease) - Overview Ankylosing Spondylitis (Bekhterev’s Disease) - Therapeutics Development Ankylosing Spondylitis (Bekhterev’s Disease) - Therapeutics Assessment Ankylosing Spondylitis (Bekhterev’s Disease) - Companies Involved in Therapeutics Development Ankylosing Spondylitis (Bekhterev’s Disease) - Drug Profiles Ankylosing Spondylitis (Bekhterev’s Disease) - Dormant Projects Ankylosing Spondylitis (Bekhterev’s Disease) - Discontinued Products Ankylosing Spondylitis (Bekhterev’s Disease) - Product Development Milestones Appendix

For more information about this report visit https://www.researchandmarkets.com/research/8hhwp4/dermatomyositis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005830/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Musculoskeletal Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 11:49 AM/DISC: 06/11/2018 11:49 AM


Update hourly